Release Date: 30 August 2023
Blincyto is a bispecific antibody developed by Amgen that was authorized in 2014 for the treatment of precursor B-cell acute lymphoblastic leukemia. The drug has since gained four additional approvals for use in various subsets of indivi...
Release Date: 30 August 2023
For several years in a row, the bispecific antibody Hemlibra has been one of Roche's best-selling medicines, and this trend was maintained in 2022 and the first half of 2023. Roche reported Hemlibra sales of CHF 2087 mill...
Release Date: 30 August 2023
Lunsumio is another bispecific antibody in Roche’s cancer drug arsenal, and is used to treat relapsed or refractory follicular lymphoma. It is also the first FDA-approved CD20andtimes;CD3 T-cell engaging bispecific ...
Release Date: 30 August 2023
Vabysmo, which was approved and launched in the market in 2022, is one of the important drugs produced by Roche that has been fueling the company’s growth and assisting it in maintaining its position as one of the w...
Release Date: 30 August 2023
Kimmtrak, developed by Immunocore, was approved to treat uveal melanoma in early 2022. It is the first bispecific antibody to be approved for the treatment of a solid tumor, as well as the first bispecific T cell engager ...
Release Date: 30 August 2023
Epkinly became the first bispecific antibody to be approved by the FDA for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in May 2023. Epkinly was developed jointly by AbbVie and Genmab and ...
Release Date: 30 August 2023
Columvi is another cancer therapeutic developed by Genentech (Roche). The drug was the first bispecific antibody to be approved for the treatment of diffuse large B-cell lymphoma. It was initially approved by Health Canad...
Release Date: 29 August 2023
The US FDA has taken a lead in the global pharmaceutical market with its precise and favorable policies that has often allowed the advent of new drug classes. One of these is bispecific antibodies, which work using the sa...
Release Date: 29 August 2023
The US FDA approved Epkinly in May 2023, making it the first bispecific antibody to be approved in 2023. Epkinly was co-developed by AbbVie and Genmab, and is indicated for the treatment of adult patients with relapsed or...
Release Date: 23 August 2023
The mounting success of monoclonal antibodies in the last few years combined with targeted drug delivery has opened another window of opportunity – the development of antibody-drug conjugates. Globally more than 15 ...
Release Date: 22 August 2023
The use of peptides as therapeutic agents benefited significantly from the discovery of insulin in 1921, which led to further research and development in this field. Since then, peptide applications have been evaluated in...
Release Date: 17 August 2023
On August 14, 2023, Pfizer’s Elrexfio (elranatamab-bcmm) became the most recent antibody to receive from the US FDA, and the 11th overall to receive an FDA approval. Elranatamab is a bispecific antibody d...
Release Date: 27 July 2023
US Orphan Drugs Market and Clinical Trials Insight 2028 Report Highlights:
Release Date: 27 July 2023
US Orphan Drugs Market, Drugs Sales, Price, Dosage and Clinical Trials Insight 2028 Report Highlights:
Release Date: 25 July 2023
US Orphan Drugs Market and Clinical Trials Insight 2028 Report Highlights: